Echocardiography in Confirmed and Highly Suspected Symptomatic COVID-19 Patients and Its Impact on Treatment Change.


Journal

Cardiology research and practice
ISSN: 2090-8016
Titre abrégé: Cardiol Res Pract
Pays: United States
ID NLM: 101516542

Informations de publication

Date de publication:
2020
Historique:
received: 28 05 2020
revised: 22 08 2020
accepted: 05 09 2020
entrez: 23 9 2020
pubmed: 24 9 2020
medline: 24 9 2020
Statut: epublish

Résumé

COVID-19 interacts at multiple levels with the cardiovascular system. The prognosis of COVID-19 infection is known to be worse for patients with underlying cardiovascular diseases. Furthermore, the virus is responsible for many cardiovascular complications. Myocardial injury may affect up to 20% of the critically ill patients. However, echocardiography's impact on the management of patients affected by COVID-19 remains unknown. To explore echocardiography's impact on the management of COVID-19 patients. This study was conducted from March 24 A total of 56 echocardiographies in 42 patients with highly suspected or confirmed COVID-19 were included in the final analyses. The median age was 66 (IQR 60.5-74). Echocardiography induced a treatment change in 9 cases (16%). The analyzed clinical data were not associated with any treatment change induced by echocardiography. D-dimer and Troponin levels were the only biological predictors of the induced treatment change. On echocardiography, higher systolic pulmonary arterial pressure and documented cardiac thrombi were associated with treatment changes in these patients. Echocardiography may be useful for the management of selected COVID-19 patients, especially those with elevated D-Dimer and Troponin levels, in up to 16% of patients.

Sections du résumé

BACKGROUND BACKGROUND
COVID-19 interacts at multiple levels with the cardiovascular system. The prognosis of COVID-19 infection is known to be worse for patients with underlying cardiovascular diseases. Furthermore, the virus is responsible for many cardiovascular complications. Myocardial injury may affect up to 20% of the critically ill patients. However, echocardiography's impact on the management of patients affected by COVID-19 remains unknown.
OBJECTIVES OBJECTIVE
To explore echocardiography's impact on the management of COVID-19 patients.
METHODS METHODS
This study was conducted from March 24
RESULTS RESULTS
A total of 56 echocardiographies in 42 patients with highly suspected or confirmed COVID-19 were included in the final analyses. The median age was 66 (IQR 60.5-74). Echocardiography induced a treatment change in 9 cases (16%). The analyzed clinical data were not associated with any treatment change induced by echocardiography. D-dimer and Troponin levels were the only biological predictors of the induced treatment change. On echocardiography, higher systolic pulmonary arterial pressure and documented cardiac thrombi were associated with treatment changes in these patients.
CONCLUSIONS CONCLUSIONS
Echocardiography may be useful for the management of selected COVID-19 patients, especially those with elevated D-Dimer and Troponin levels, in up to 16% of patients.

Identifiants

pubmed: 32963823
doi: 10.1155/2020/4348598
pmc: PMC7495215
doi:

Types de publication

Journal Article

Langues

eng

Pagination

4348598

Informations de copyright

Copyright © 2020 Nadia Benyounes et al.

Déclaration de conflit d'intérêts

The authors do not report any relevant conflicts of interest in relation to this article.

Références

JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Cardiol Res Pract. 2020 Feb 28;2020:8076582
pubmed: 32190384
Eur Heart J. 2020 May 14;41(19):1860
pubmed: 32285915
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Am Coll Cardiol. 2020 Jun 23;75(24):3078-3084
pubmed: 32272153
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
J Am Coll Cardiol. 2017 Mar 21;69(11):1451-1464
pubmed: 28302294
Eur Heart J. 2020 May 14;41(19):1859
pubmed: 32282027
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
Nat Rev Cardiol. 2020 May;17(5):259-260
pubmed: 32139904
J Am Soc Echocardiogr. 2016 Apr;29(4):277-314
pubmed: 27037982
Arch Cardiovasc Dis. 2016 Oct;109(10):533-541
pubmed: 27344376
Am Heart J. 2020 Jul;225:3-9
pubmed: 32417526
Arch Cardiovasc Dis. 2015 Jan;108(1):50-6
pubmed: 25530159
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Clin Res Cardiol. 2020 May;109(5):531-538
pubmed: 32161990
Eur Heart J. 2020 May 14;41(19):1858
pubmed: 32227120
Heart Fail Rev. 2020 Jan;25(1):9-17
pubmed: 31317296
JAMA Cardiol. 2020 Jul 1;5(7):802-810
pubmed: 32211816
Eur Heart J. 2020 May 14;41(19):1861-1862
pubmed: 32267502
Circulation. 2020 Jun 2;141(22):1733-1735
pubmed: 32251612

Auteurs

Nadia Benyounes (N)

Cardiology Unit, Rothschild Foundation Hospital, Paris, France.

Clélie Van Der Vynckt (C)

Cardiology Unit, Rothschild Foundation Hospital, Paris, France.

Séverine Tibi (S)

British Library, London, UK.

Alexandra Iglesias (A)

Alsacienne School, Paris, France.

Laurence Salomon (L)

Clinical Research Department, Rothschild Foundation Hospital, Paris, France.

Olivier Gout (O)

Neurology Department, Rothschild Foundation Hospital, Paris, France.

Thierry Tibi (T)

Cardiology Unit, Rothschild Foundation Hospital, Paris, France.

Classifications MeSH